|
|
|
| home > ebr > Summer 2004 |
|
|
 PUBLICATIONS |
European Biopharmaceutical Review |
|
|
|
|
| At the cutting edge of the latest industry developments, Samedan is adept at keeping the information you need at your fingertips. EBR provides a unique platform of communication for the market across Europe, North America and the rest of the developed world. To find out what's hot in the world of of biopharmaceuticals, take a look below at the range of articles featured in this issue of EBR. |
 |
| |
|
|
| In her Editor's Letter, Dr Helen Abbott reviews the hot topics in this issue |
|
|
|
|
| Beating Cancer Cells at their own Game: Professor Lindy Durrant of Scancell Ltd, Professor Stephen P Jackson of KuDOS Pharmaceuticals Ltd and Dr Klaus Giese of atugen AG, investigate the story |
|
|
| Rajaram Sankaran, Industry Analyst with Frost & Sullivan's Technical Insights Division, reveals a Panacea in the Pipeline - Promising Drug Development Efforts Offer Hope to Cancer Patients |
|
|
| Peter M Fischer, Head of Discovery Research at Cyclacel Limited, investigates Apoptosis and Chemotherapy: Helping Cancer Cells to Die |
|
|
|
| Mark Clement, Chief Executive of Merlin Biosciences, examines the current climate for Investing in European Life Sciences |
|
|
| Dr Konrad Burk of ClinDescience GmbH, Dr William McCulloch of Gloucester Pharmaceuticals, Dr Alexander von Nieciecki of BioProof, and Dr Wolfgang Meyer and Dr Benno Rattel of GPC Biotech AG, ask Why is Scientific Due Diligence Essential in Drug Development? |
|
|
| Effective responses to new investment opportunities are hampered by lack of preparation, contend Patrick Martin, Partner and Martin Finnegan, Senior Solicitor at McGrigors, in The IPO Window Reopens - Are you Ready? |
|
|
| Nigel Sheail, Global Head, Strategic Alliances & Acquisitions at Roche Pharma, discusses Driving Productivity through Strategic Partnering |
|
|
|
| In Maximise the Return on Ethics Consultations by Minimising Deficit Thinking, Dr Andrew Smart, Sociology Research Officer for the Oxford Genetics Knowledge Park and Dr Kevin E Jones, Senior Research Associate at Brunel University, argue that deeply embedded assumptions about knowledge and expertise may curtail positive outcomes |
|
|
| Dr Sandy Thomas, Director of the Nuffield Council on Bioethics, considers the ethical, legal, regulatory and social issues that may be raised as research progresses towards application in A Discussion of the Ethical Issues which Surround Pharmacogenetics |
|
|
| Dr Delon Human, Secretary General of the World Medical Association, discusses the pre-eminent ethical guide on health care research in, The Declaration of Helsinki: Protecting Patient Rights in Biomedical Research Drug Discovery Technologies |
|
|
| Dr Mark C Field, Department of Biological Sciences at Imperial College, London, and Dr Mark Carrington, Department of Biochemistry at the University of Cambridge, UK, explore Functional Genomics in Trypanosomes: Using RNA Interference to Assign Gene Function and Validate Drug Targets in Tropical Disease Agents |
|
|
| Elucidation of genetic factors in causation and new treatments will be accelerated as Fully Automated Storage Creates an Open Source for Genetic Epidemiology, say Dr Martin Yuille, Chief Scientific Officer and Dr Cheng-Eng Ang, MRC DNA Banking Network Manager at MRC geneservice |
|
|
| Stephanie Fulmer-Smentek, Senior R&D Research Scientist at Agilent Technologies Inc and Luis Lombardia, Research Associate at Centro Nacional de Investigaciones Oncologicas (CNIO), explore the Performance Comparison of 60-mer and 25-mer In Situ Synthesised Oligonucleotide Microarrays |
|
|
| Dr Christian Bailly of Pierre Fabre, Dr David Wilson of Georgia State University, USA, and Dr Alan McWhirter of Biacore AB, assert that investigation of alternative drug targets is imperative in Optimising DNA-Binding Characteristics of Anticancer and Antiparasitic Drugs |
|
|
|
| In Drugs for Life - How 'Lifestyle' Medicines can Lead the Way to Healthy Profits, Chris Every, CEO of Enhance Biotech outlines the era of 'wellbeing' 88 Katherine Sacksteder, Director of Communications at Sequella, Inc, presents methods of navigating hurdles in the face of a tight budget, in Clinical Trial Challenges for Biotech Start-ups |
|
|
| Adding Value in Exploratory Drug Development: Daryl Bendel, Managing Director of Charterhouse Clinical Research Unit Limited, and Rukhsana Ahsan, Laboratory Director of Clinical Trials Laboratory Services, explore The Clinical Trials Centre/Clinical Trials Laboratory Interface |
|
|
| Michael R Hamrell, President of MORIAH Consultants, considers the continually evolving Preclinical Safety Assessment of Biologic Products |
|
|
| Therapeutic proteins constitute a significant proportion of the global market, but experience and know-how is essential to high quality production, says Tony Hitchcock, Associate Director of Microbial Products at Cobra in Manufacturing Recombinant Proteins: Facing up to the Challenges of Making Tomorrow's Medicines |
|
|
|
| Ylva Williams, Head of Life Sciences at the Invest in Sweden Agency, provides an insight into future challenges for Europe's fourth largest biotech country, in Sweden: Building Better Biotechnology |
|
|
| Cross Border Research and Innovation in Medicon Valley - Stina Gestrelius and Anette Birck at Medicon Valley Academy offer an introduction to the region |
|
|
| The knowledge-based growth strategy of Finland strongly supports research and development, explains Saara Hassinen, Assistant Director of Finnish Bioindustries in Biotechnology Industry in Finland |
|
|
| Dr Beat E Glatthaar, Swiss General Manager of BioValley, reviews BioSquare 2004 in Basel - A Successful Get Together for Biotech in the BioValley |
|
|
|
|
|
 |
|
|
 |
News and Press Releases |
 |
Catalent Signs Commercial Supply Agreement with Blueprint Medicines Following FDA Approval of GAVRETOT (pralsetinib)
Catalent, the leading global provider of advanced delivery technologies,
development, and manufacturing solutions for drugs, biologics, cell and
gene therapies, and consumer health products, today announced that it
had entered into a commercial supply agreement with Blueprint Medicines
following FDA approval of GAVRETO™ (pralsetinib). Developed by Blueprint
Medicines, GAVRETO is a new therapy indicated for the treatment of
adults with metastatic RET fusion-positive non-small cell lung cancer
(NSCLC) as detected by an FDA approved test.
More info >> |
|
 |
White Papers |
 |
|
Assessing the Integrity of Pharmaceutical Packaging Using the Sepha Blisterscan and Conventional Blue Dye Leak Testing Methods
Sepha Limited
A new whitepaper by a leading packaging expert from the University of Ulster, Dr Dorian Dixon, into the integrity of pharmaceutical packaging has established that existing methods for testing the seal integrity of blister packs are not as accurate as newer, technology based test equipment.
More info >> |
|
|
.jpg)
